Missed Opportunities on Emergency Remdesivir Use

JAMA. 2020 Jul 28;324(4):331-332. doi: 10.1001/jama.2020.11932.

Authors

Ameet Sarpatwari¹, Anna Kaltenboeck², Aaron S Kesselheim¹

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Drug Pricing Lab, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York.

PMID: 32579163
DOI: 10.1001/jama.2020.11932

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenosine Monophosphate / adverse effects
Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / economics
Adenosine Monophosphate / supply & distribution
Adenosine Monophosphate / therapeutic use
Alanine / adverse effects
Alanine / analogs & derivatives*
Alanine / economics
Alanine / supply & distribution
Alanine / therapeutic use
Antiviral Agents / adverse effects
Antiviral Agents / economics
Antiviral Agents / supply & distribution
Antiviral Agents / therapeutic use*
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Clinical Trials, Phase III as Topic
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Drug Approval
Drug Costs
Drugs, Investigational / adverse effects
Drugs, Investigational / economics
Drugs, Investigational / supply & distribution
Drugs, Investigational / therapeutic use*
Hemorrhagic Fever, Ebola / drug therapy
Humans
Length of Stay
National Institute of Allergy and Infectious Diseases (U.S.)
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Registries
SARS-CoV-2
Treatment Outcome
United States / epidemiology

Substances

Antiviral Agents
Drugs, Investigational
remdesivir
Adenosine Monophosphate
Alanine